TC BioPharm Begins Dosing Phase 2B Clinical Study Evaluating its Lead Compound, OmnImmune, in Patients with Acute Myeloid Leukemia
EDINBURGH, Scotland, Nov. 22, 2022. TC Biopharm (Holdings) PLC ( " TC Biopharm " or the " Company " ), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer today announced the dosing of its first... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 22, 2022 Category: Pharmaceuticals Source Type: clinical trials
Assessment of a Robotic Exoskeleton for Upper Limb Rehabilitation
Condition: Spinal Cord Injuries Intervention: Device: Experimental: Device Intervention Sponsors: University of Liverpool; Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust; The Queen Elizabeth National Spinal Injuries Unit, Scotland; Stoke Mandeville Spinal Research Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 14, 2022 Category: Research Source Type: clinical trials